Zacks14d agobullish
Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance RaisedBiogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
322last 24h
2135last 7d
379● bullish (7d)
186● bearish (7d)
204publishers
Investing.com30d agobullish
Truist upgrades Biogen to Buy on Alzheimer’s, pipeline optimism ahead of key dataInvesting.com -- Truist Securities upgraded Biogen to Buy from Hold and raised its price target to $235 from $190, citing growing confidence in the company’s Alzheimer’s and immunology pipeline ahead of several major clinical data readouts over the next two years.